Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity. This is further to the company?s previous intimation of 27 March 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva. The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
310.3 INR | +3.94% | +10.69% | +24.21% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
310.2 INR | +3.90% | +10.73% | 4.27B | ||
3.26 RON | +0.62% | -0.61% | 488M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.25% | 4.27B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.70% | 22.25B | |
-14.77% | 21.68B | |
-8.68% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution